Oppilotech Ltd, a biopharmaceutical start-up company founded to develop safe, novel, antibacterial therapies to treat bacterial infections, has been selected for funding by a new public-private partnership, CARB-X – The Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator.
Oppilotech’s programme, funded by CARB-X, is a 6-month project to undertake early screening work against a novel target involved in making a major constituent found on the outer envelope of Gram-negative bacteria.
The work is aimed at developing a new class of antibiotics, a significant goal as it has been more than 25 years since a new class was approved to treat acute infections.
Being part of CARB-X not only allows access to capital but also to a range of expertise including drug development and regulatory services.
CARB-X was launched jointly by the US Department of Health and Human Services (HHS), Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID).
It aims to address the urgent threat of antibiotic resistant bacteria which kills 700,000 people a year globally.
CARB-X is funded by BARDA and the Wellcome Trust, a global charitable foundation, and aims to invest up to $450 million in 5 years.
Its goal is to accelerate the preclinical discovery and development of at least 20 new antibacterial products, and progress at least two new products into human trials during that time.
Ajay Mistry, PhD, Founder/CEO of Oppilotech, stated: “We are delighted to be one of the first portfolio companies selected by CARB-X. Our project was vetted by leading antibiotic experts on the CARB-X Advisory Board and is a reflection of the high quality science we are pursuing to develop our pipeline of new antibacterials.”